221 related articles for article (PubMed ID: 19491050)
1. Growth and profitability in small privately held biotech firms: preliminary findings.
Brännback M; Carsrud A; Renko M; Ostermark R; Aaltonen J; Kiviluoto N
N Biotechnol; 2009 Jun; 25(5):369-76. PubMed ID: 19491050
[TBL] [Abstract][Full Text] [Related]
2. Private biotech 2004--the numbers.
Hodgson J
Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
[TBL] [Abstract][Full Text] [Related]
3. Lack of private financing hobbles emerging biotech regions.
Jia H; Jayarama KS; Astvatsaturyan M
Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
[No Abstract] [Full Text] [Related]
4. An empirical investigation of hospital profitability in the post-PPS era.
Younis M; Rice J; Barkoulas J
J Health Care Finance; 2001; 28(2):65-73. PubMed ID: 11794758
[TBL] [Abstract][Full Text] [Related]
5. IPOs: the narrow window closes?
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
[No Abstract] [Full Text] [Related]
6. Cash-strapped biotechs find financing alternative.
Mitchell P
Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
[No Abstract] [Full Text] [Related]
7. Shift toward early-stage deals favors biotechs.
Lawrence S
Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
[No Abstract] [Full Text] [Related]
8. Another clue to biotech value.
Jacobs T
Nat Biotechnol; 2003 Jul; 21(7):746. PubMed ID: 12833091
[No Abstract] [Full Text] [Related]
9. Public biotech 2007--the numbers.
Lawrence S; Lähteenmäki R
Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
[TBL] [Abstract][Full Text] [Related]
10. Napster case spills into biotech sector.
Bouchie A
Nat Biotechnol; 2004 Sep; 22(9):1185-6. PubMed ID: 15384189
[No Abstract] [Full Text] [Related]
11. Public biotechnology 2003-the numbers.
Lähteenmäki R; Baker M
Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
[No Abstract] [Full Text] [Related]
12. Hedge funds gain edge by doubling biotech investments.
Ransom J
Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
[No Abstract] [Full Text] [Related]
13. My worst biotech investment.
Jacobs T
Nat Biotechnol; 2006 Apr; 24(4):401. PubMed ID: 16601718
[No Abstract] [Full Text] [Related]
14. A special biotech speculation.
Jacobs T
Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
[No Abstract] [Full Text] [Related]
15. Biotech holds steady in Q4.
Mitchell P
Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
[No Abstract] [Full Text] [Related]
16. Beware the biotech barker.
Jacobs T
Nat Biotechnol; 2005 May; 23(5):538. PubMed ID: 15877065
[No Abstract] [Full Text] [Related]
17. Biotech IPOs: handle with care.
Jacobs T
Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
[No Abstract] [Full Text] [Related]
18. Biotech IPOs--flop or pop?
Jacobs T
Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
[No Abstract] [Full Text] [Related]
19. Chasing biotech, state by state--winners and losers.
Wilan KH
Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
[No Abstract] [Full Text] [Related]
20. A taxing dilemma.
Jacobs T
Nat Biotechnol; 2005 Oct; 23(10):1219. PubMed ID: 16211056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
